A report from China Daily https://mma.prnewswire.com/media/2804498/1.jpg Nearly 450 billion yuan ($63 billion) has been invested in mineral exploration and 150 new mineral deposits have been discovered nationwide during the 14th Five-Year Plan (2021-25) period, the Ministry of Natural Resources announced on Thursday. According to the China Mineral Resources (2025) report unveiled by the ministry at […]

Crowded is recognized for its innovative financial-management platform for nonprofits, and reinforces its commitment to donation transparency amid a recent industry scandal. https://mma.prnewswire.com/media/2804439/Crowded_CB_Insights_2025.jpg CB Insights today named Crowded, a Miami-based fintech platform for nonprofit financial management, to its eighth annual Fintech 100, showcasing the 100 most promising private fintech companies in the world. “This year's

Iron Software has announced theIronPDF Developer Writing Contest, offering $10,000 in cash and prizes to .NET developers who share real-world tutorials and insights on how theyuse C# to create a PDF in production environments. The initiative celebrates innovation within the developer community and highlights Iron Software's ongoing commitment to supporting the .NET ecosystem as government

— In line with the vision of His Highness SheikhMohamed bin Zayed Al Nahyan, President of the United Arab Emirates, world-first project reaffirms UAE's leadership position in clean energy, directly addressing intermittency of renewables — Project will reimagine potential of renewable energy, delivering 1GW of baseload power at a globally competitive tariff, establishing a blueprint

(NasdaqGM:CSTL), This new histological subtype data confirms DecisionDx-Melanoma's clinical value across the spectrum of melanoma Castle Biosciences will also present validation data on its atopic dermatitis pipeline test FRIENDSWOOD, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that

New Analysis of 13,560 Patients Demonstrates DecisionDx(R)-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference GlobeNewswire October 24, 2025 This new histological subtype data confirms DecisionDx-Melanoma's clinical value across the spectrum of melanoma Castle Biosciences will also present validation data on its atopic dermatitis pipeline test FRIENDSWOOD, Texas, Oct.

(NASDAQ:GNTA), MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) — Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with a focus on off-the-shelf lentiviral vector (“LVV”) Plasmid DNA technology platform. This new agreement builds and expands on the existing

Pony.ai, a leading autonomous driving technology company, today announced the rollout of its 300th jointly manufactured ARCFOX Alpha T5 Robotaxi – a significant production milestone that accelerates the company's trajectory toward large-scale deployment and commercialization. The rollout ceremony was attended by Dr. James Peng, Founder and CEO of Pony.ai, and Yu Liu, Vice General Manager

Renalys Pharma, Inc. (Headquarters: Tokyo; Representative Director Chaiman & CEO; BT Slingsby; “Renalys”) and Chugai Pharmaceutical Co., Ltd. (Headquarters: Tokyo; President & CEO: Osamu Okuda; “Chugai”) today announced a definitive stock purchase agreement, under which Chugai will acquire Renalys (the “Transaction”). Renalys is advancing sparsentan in Japan; the medicine was initially developed by Travere Therapeutics,

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production GlobeNewswire October 24, 2025 MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) — Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with a focus on off-the-shelf